Tillomed acquires Manx Healthcare’s pharma portfolio for £19.7 million 

Tillomed Laboratories Ltd is the European subsidiary of Emcure Pharmaceuticals 
| Photo Credit:
utah778

Tillomed Laboratories Ltd, the European subsidiary of Emcure Pharmaceuticals, has acquired the pharmaceutical portfolio of UK-based Manx Healthcare Ltd and its subsidiaries in a deal valued at approximately £19.7 million, the company announced today.

The shares of Emcure Pharmaceuticals were trading at ₹987.95 down by ₹45.30 or 4.38 per cent on the NSE at the closing bell today.

The Asset Purchase Agreement includes Manx’s product portfolio, relevant dossiers, marketing authorisations, intellectual property rights, and inventory. The acquisition structure involves an upfront payment of £6.2 million, with the remaining amount to be paid as milestone payments over the next 18 months.

“Through the acquisition of Manx’s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions,” said Ajit Srimal, CEO of Tillomed. “The acquired assets will help diversify our portfolio and strengthen our market presence.”

Tillomed, headquartered in Luton, UK, currently markets over 100 pharmaceutical products across multiple European markets. The acquisition is expected to expand its market reach and enhance its ability to meet patient needs with an expanded product line.

Emcure Pharmaceuticals, the parent company of Tillomed, is ranked the 12th largest pharmaceutical company in India, based on domestic sales as of June 2024. Established in 1981, Emcure operates in more than 70 countries worldwide, including Europe and Canada.

Published on April 4, 2025